Phase 3 trial results show roflumilast cream 0.05% to be a safe and effective treatment for children with atopic dermatitis.

A subset of patients treated with delgocitinib cream 20 mg/g for moderate to severe chronic eczema achieved a “super-response,” by week 16, according to a presenter at the American Academy of ...

Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...

The following is a summary of “Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic ...

In addition to using it as an eczema treatment, I noticed my acne looked ... Usually, to get these results, I would have to use a prescription cream, but that could take a few days to a few ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...

A new survey commissioned by Leo Pharma confirms there’s plenty of room in the market for its chronic hand eczema treatment ...

Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...

Many TikTokers attest to its deeply hydrating and skin-improving ability — notably, former reality TV star Lo Bosworth, who ...

This NIHR Collection brings together major studies on the prevention and treatment of childhood eczema. It finds that many ...

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup ...

Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according to a study published online Feb. 20 in Pediatric Dermatology.